Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3665578 | 0.99 | GSK3B (0.47) | GSK3BCYP2D6P2RY12CYP3A4CYP2C9 | |
| SCHEMBL914927 | 0.91 | GSK3B (0.47) | GSK3BCYP2D6P2RY12CYP3A4L3MBTL1 | |
| SCHEMBL3654635 | 0.84 | GSK3B (0.46) | GSK3BCYP2D6P2RY12SCDSCD5 | |
| SCHEMBL3665141 | 0.84 | GSK3B (0.45) | GSK3BCYP2D6CYP3A4CYP1A2 | |
| SCHEMBL3664584 | 0.82 | GSK3B (0.46) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL1168728 | 0.82 | GSK3B (0.49) | GSK3BCYP2D6 | |
| SCHEMBL916300 | 0.82 | GSK3B (0.49) | GSK3BCYP2D6 | |
| SCHEMBL1832106 | 0.82 | GSK3B (0.49) | GSK3BCYP2D6 | |
| Bromide SCHEMBL3660416 | 0.81 | GSK3B (0.49) | GSK3BCYP2D6 | |
| SCHEMBL1168937 | 0.81 | GSK3B (0.46) | GSK3BP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238141-B1 | SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA | SANOFI SA (FR) | 2015-01-14 | — | — | EP | disclosed |
| US-8507476-B2 | Substituted arylamide diazepinopyrimidone derivatives | SANOFI (FR) | 2013-08-13 | — | — | US | disclosed |
| EP-2238141-A1 | SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| EP-2090578-A1 | Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta | Sanofi-Aventis (FR) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009095789-A1 | SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | disclosed |